Oral Insulin May Delay Type 1 Diabetes Onset in 'Responders'

Marlene Busko

June 23, 2017

SAN DIEGO — Close relatives of people with type 1 diabetes who had certain autoantibodies believed to put them at high risk of progression to clinical type 1 diabetes did not benefit from taking oral insulin vs placebo, in a new trial. The participants were mostly children and adolescents, with a median age of 8.

However, "surprisingly," among a small subset of participants with the same autoantibodies against islet cells but with low  insulin secretion, those who received insulin tablets were diagnosed with type 1 diabetes 2.5 years later than those who got placebo.

Thus, although the TrialNet Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus trial was negative in the "main stratum" of studied patients, "nonetheless this dramatic result in...this subset of patients" is definitely something to follow up with in future research," Carla Greenbaum, MD, from Benaroya Research Institute, in Seattle, Washington, said at the American Diabetes Association (ADA) 2017 Scientific Sessions.

And this is, she stressed, "the largest trial ever performed using oral insulin."

"Delaying diabetes by a day, by a week, by a month...is so clearly important," Desmond A Schatz, MD, from University of Florida, Gainesville, emphasized. "We've got to define these responders."

The assigned discussant at this session was even more positive. "Is this a negative study? It was perhaps not the home run that we all hoped for, but a prespecified secondary hypothesis was met," noted David M Maahs, MD, from Stanford University, California.

Moreover, "there were no significant adverse events....I do think it is significant to be able to delay type 1 diabetes for 2.5 years in a subset," he said, adding, "It's not perhaps the victory we hoped for, but certainly an incremental advance."

Four Types of Islet Autoantibody Profiles

People with close relatives with type 1 diabetes have a 15-fold increased risk of developing the disease themselves, Dr Greenbaum noted.

An earlier study had suggested that if such individuals also had high levels of micro insulin autoantibodies (mIAA), taking oral insulin might buy time until they were diagnosed with the same disease.

Thus, the researchers aimed to determine if insulin tablets might delay or prevent type 1 diabetes in high-risk individuals with high levels of mIAA plus certain other islet autoantibodies (the primary outcome).

They also aimed to gather information from individuals with different profiles of islet autoantibodies (secondary outcomes).

From 2007 to 2015, the researchers screened almost 140,000 individuals who had a close relative with type 1 diabetes at 87 sites in eight countries, and they enrolled 560 individuals.

Participants were either 3 to 45 years old with a first-degree relative (child, parent, or sibling) with type 1 diabetes or 3 to 20 years old with a second-degree relative (uncle, aunt, niece, nephew, cousin, or grandparent) with type 1 diabetes.

The enrolled subjects had a median age of 8.25.

They were in phase 1 of the continuum of type 1 diabetes disease progression. That is, they had normal blood glucose and two or more islet autoantibodies, including mIAA, islet-cell antibodies (ICA), glutamic acid decarboxylase (GAD) antibodies, or islet antigen-2 (IA-2) antibodies.

The study subjects were then divided into four groups:

  • Primary stratum: 389 participants with mIAA and ICA or GAD plus IA-2 and high insulin secretion (above threshold).

  • Secondary stratum 1: 55 patients with mIAA and ICA or GAD plus IA-2 and low insulin secretion.

  • Secondary stratum 2: 114 patients with mIAA and GAD or IA-2 and high insulin secretion.

  • Secondary stratum 3: Two patients with mIAA and GAD or IA-2, and low insulin secretion.

In each group, subjects were randomized to receive 7.5 mg/day of oral insulin or placebo. They had oral glucose-tolerance tests every 6 months to assess if they had developed type 1 diabetes.

In the primary-stratum group, 8.8% of subjects treated with oral insulin vs 10.2% of subjects who received placebo developed diabetes each year, during an 8-year follow-up, which was not a significant difference (HR, 0.87; = .42).

Similarly, oral insulin did not have a significant effect on the development of type 1 diabetes in the combined secondary-strata 2 and 3 groups or in the overall study sample.

However, in the secondary-stratum 1 group, 18.1% of those treated with oral insulin vs 34.1% of subjects who received placebo developed diabetes each year during follow-up, which was a significant 55% reduction (HR 0.45; 95% CI, 0.22–0.91; = .01).

This translated into a 2.5-year delay in the median time to type 1 diabetes with oral insulin in this subgroup.

"Not Everyone Develops Diabetes in the Same Way"

"We wanted to know if the drug worked and whether it would be limited to that group [identified in an earlier study] or whether others would potentially benefit as well," Dr Greenbaum commented to Medscape Medical News.

"This result further supports our understanding that not everyone develops type 1 diabetes in the same way and is an early step toward developing specific targeted therapies," she emphasized.

Dr Schatz said: "Clearly more research is needed to explore why certain people may respond to oral insulin and others don't."

The study drug was provided by Eli Lilly. Dr Greenbaum has served as an advisor for Lilly, Novo Nordisk, Bristol Meyers Squib, and Pfizer and has research funding from Janssen and Novo Nordisk. Dr Schatz has no relevant financial relationships. Dr Maahs is a speaker and on the advisory panel for Insulet and is a speaker and consultant for Abbott. He is a speaker for and receives research support from Medtronic, Dexcom, Bigfoot, Insulet, and Roche. He was part of the investigational team and provided recruitment assistance when he was at the Barbara Davis Center, Aurora, Colorado.

For more diabetes and endocrinology news, follow us on Twitter and on Facebook.

American Diabetes Association 2017 Scientific Sessions; June 12, 2016; San Diego, California. Type 1 Diabetes Immune Intervention Trials. Session 5-IT-SY07


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.